Time-restricted eating to address persistent cancer-related fatigue among cancer survivors: A randomized controlled trial

Res Sq [Preprint]. 2024 Dec 25:rs.3.rs-5530166. doi: 10.21203/rs.3.rs-5530166/v1.

Abstract

Purpose: Time-restricted eating (TRE) helps regulate rest-activity rhythms, blood glucose, and other diurnally regulated energetics processes, which may have implications for persistent fatigue. In a randomized controlled trial, we tested the effects of TRE vs. control on fatigue in cancer survivorship. Methods: Adult cancer survivors were recruited who were 2 months to 2 years post-treatment and reported moderate to severe fatigue. Participants were randomized 1:1, TRE:control and all received individualized nutrition counseling. The TRE group self-selected a 10-hour eating window for 12 weeks. At baseline, week 6, and week 12, participants were asked to log eating instances, complete the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire (FACIT-F, higher score=less fatigue), and wear an actigraph and continuous glucose monitor. Results: Thirty participants completed baseline assessments and were randomized (77% female, 53% Black/African American, 43% White, 7% Hispanic; 54.1±14.7 years old; 87% with blood cancer); 25 completed 12-week assessments. TRE led to a meaningful reduction in fatigue at week 12 controlling for baseline levels (change in FACIT-F fatigue subscale=0.0±5.4 for control, 4.1±5.7 for TRE, p =0.11, effect size [ES]=0.70; clinically meaningful threshold=3.0 points). Glucose parameters (e.g., average interstitial glucose, average fasting glucose) tended to be lower and rest-activity rhythms tended to indicate more regularity for those in the TRE vs. control group at weeks 6 and 12, though differences were not statistically significant ( p >0.19). Conclusions: A 12-week, nutritionist-led TRE program led to less fatigue than control. Continued study of TRE patterns are warranted to optimize this eating pattern and address persistent cancer-related fatigue. Clinicaltrials.gov identifier: NCT05256888, registered 02/2022.

Publication types

  • Preprint

Associated data

  • ClinicalTrials.gov/NCT05256888